News

Mile Brujic, OD, FAAO, details his presentation on how eye care providers can best equip themselves with identifying and mitigating toxicities caused by antibody drug conjugates.

New phase 3 trial tests rhNGF eye drops for persistent corneal epithelial defects, aiming for full healing and a first approved PCED therapy.

The company said the expanded portfolio will be available in the US and Canada this summer.

The investment will expand ACUVUE contact lens manufacturing and distribution in Jacksonville, improving supply chain stability for optometrists by 2028.

A newly developed diagnostic system, CaptureTumor (CaT), driven by AI and designed specifically for smartphone deployment, achieved diagnostic accuracy comparable to that of a specialist-graded slit-lamp evaluation for detecting rare ocular surface malignancies.

In this podcast, experts Francis Mah, MD; and Amy Nau, OD, FAAO, Dipl, CCLRT; discuss how to identify neurotrophic keratitis in practice, highlighting indications for corneal sensitivity testing based on patient history and examination findings. Faculty will also examine how to stage and treat neurotrophic keratitis once diagnosed.

The update introduces a 250 kHz scan speed for OCT Angiography combined with enhanced TruTrack Active Eye Tracking, as well as new multimodal imaging capabilities, including the Green Autofluorescence Module.

Epion completes phase 3 follow-up for EpiSmart epi-on corneal cross-linking in keratoconus, advancing toward FDA NDA and a less painful alternative.

A case study that highlights the importance of multimodal imaging in practice for early identification of rare inherited retinal dystrophies.

The lens is scheduled to become available in the US in fall 2026.

The study, conducted through the OHDSI network, analyzed records from 227,971 new users of semaglutide.

Daniel C. Brocks, MD, BostonSight chief medical officer, discusses a few of the company's studies, the patients they serve, and what the broader eye care community may be missing.

The free web-based tool guides eye care providers through evidence-based amblyopia diagnosis and treatment without requiring pediatric subspecialty training.

LENZ Therapeutics licenses FDA-approved presbyopia drop to Everest Medicines for Greater China; NDA under review by NMPA with approval anticipated in Q1 2027.

Researchers analyzed data from 13 randomized controlled trials involving children and adolescents with myopia.

Clark Chang, OD, MSA, MSc, FAAO, FSLS, and Susan Gromacki, OD, MS, FAAO, FSLS, provide insights into their expertise.

The strength of our referral relationships defines the quality of our patients' eye health journey.

Mile Brujic, OD, FAAO, details his experience in manufacturing his new ScleralEase device and what other ODs can learn from his experience.

Researchers from Yale School of Medicine weigh in on what everyday clinicians can take away from their findings.

Myopia management is rarely straightforward.

The topical synthetic peptide receives orphan drug and fast track status and enters phase 2 as a first-in-class treatment for a rare degenerative corneal disease.

Yale School of Medicine researchers outline their findings and the methods of their researcher in an exclusive interview with Optometry Times.

A pilot study shows that analyzing how the cornea moves under air-puff stimulation may improve early keratoconus detection.

The university received $29.8 million through the state's Amended Fiscal Year 2026 Budget to renovate the Highway 301 building in Statesboro and create a facility to house the new program.

The product is expected to be available in stores and online at Amazon, CVS, Target and Walgreens by the end of June 2026.

The resubmission follows a successful appeal by the company with the Office of New Drugs (OND).

Host Hamza Shah, OD, MS, FAAO, is joined by Kaleb Abbott, OD, MS, to discuss eye care terminology, inspired by Abbott and Pucker's paper, "It's time to retire the terms artificial tears and rewetting drops: A call for accurate terminology and updated clinical usage in eye care."

The benefits of consistent physical activity have been demonstrated for a host of systemic conditions.